Attached files

file filename
EX-99.4 - EX-99.4 - Loxo Oncology, Inc.a17-14662_1ex99d4.htm
EX-99.5 - EX-99.5 - Loxo Oncology, Inc.a17-14662_1ex99d5.htm
EX-99.3 - EX-99.3 - Loxo Oncology, Inc.a17-14662_1ex99d3.htm
EX-99.2 - EX-99.2 - Loxo Oncology, Inc.a17-14662_1ex99d2.htm
EX-99.1 - EX-99.1 - Loxo Oncology, Inc.a17-14662_1ex99d1.htm

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 8-K

 

CURRENT REPORT PURSUANT TO

SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report: June 3, 2017

(Date of earliest event reported)

 

LOXO ONCOLOGY, INC.

(Exact Name of Registrant as Specified in Its Charter)

 

Delaware

(State or Other Jurisdiction of Incorporation)

 

001-36562

 

46-2996673

(Commission File Number)

 

(IRS Employer Identification No.)

 

 

 

281 Tresser Blvd., 9th Floor
Stamford, CT

 

06901

(Address of Principal Executive Offices)

 

(Zip Code)

 

(203) 653-3880

(Registrant’s Telephone Number, Including Area Code)

 

Not Applicable

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x

 

 

 



 

Item 7.01 Regulation FD.

 

On June 3, 2017, Loxo Oncology, Inc. (“Loxo Oncology”) issued two press releases. One press release announced updated clinical data for Loxo Oncology’s ongoing larotrectinib trials as reported by study investigators at the 2017 American Society of Clinical Oncology Annual Meeting (“ASCO”) in Chicago. The second press release announced a clinical proof of concept publication for next-generation TRK inhibitor LOXO-195. A copy of the press releases are furnished as Exhibit 99.1 and 99.2, respectively, to this report and incorporated herein by reference. A copy of the slides presented by the study investigators at ASCO are furnished as Exhibit 99.3 and Exhibit 99.4 to this report and incorporated herein by reference.

 

On June 4, 2017, Loxo Oncology held an investor conference call. A copy of the slides presented during the investor conference call are furnished as Exhibit 99.5 to this report and incorporated herein by reference.

 

The information furnished with this report, including Exhibit 99.1, Exhibit 99.2, Exhibit 99.3, Exhibit 99.4 and Exhibit 99.5, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

Item 9.01 Financial Statements and Exhibits

 

(d) Exhibits.

 

Exhibit

 

 

Number

 

Description of Exhibit

 

 

 

99.1

 

Press release dated June 3, 2017.

 

 

 

99.2

 

Press release dated June 3, 2017.

 

 

 

99.3

 

Slides presented by study investigators on June 3, 2017.

 

 

 

99.4

 

Slides presented by study investigators on June 5, 2017.

 

 

 

99.5

 

Slides presented by Loxo Oncology on June 4, 2017.

 

2



 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

Loxo Oncology, Inc.

 

 

Date: June 5, 2017

By:

/s/ Jennifer Burstein

 

Name:

Jennifer Burstein

 

 

 

 

Title:

Vice President of Finance and principal financial officer

 

3